Symbicort Lawsuit

Filing a Symbicort lawsuit is an option for COPD patients who suffered a heart attack, stroke or other cardiovascular event within the first 30 days initiating treatment with this long-acting inhaler medication.

Contact a Symbicort Lawyer Today

The Symbicort lawyers are Bernstein Liebhard LLP are offering free legal reviews to COPD patients who experienced serious heart problems within 30 days of starting treatment with this medication, including:

  • Coronary heart disease
  • Cardiac arrhythmia
  • Heart failure
  • Heart attack
  • Ischemic stroke

To learn more about filing a Symbicort lawsuit, please call (888) 994-5118.

Symbicort: What’s the Problem?

Symbicort (budesonide and formoterol fumarate dihydrate) is an inhaled maintenance medication indicated to treat people who suffer from asthma and COPD, including chronic bronchitis and emphysema.

Budesonide is an inhaled corticosteroid that reduces inflammation in the airways. Formoterol belongs to a class of long-acting bronchodilators called inhaled long-acting β2-agonists (LABAs), which prevent bronchospasm by relaxing the muscles around the airways.

In January 2018, a study published in JAMA Internal Medicine found that patients who began using certain long-acting inhalers, including LABAs such as formoterol, were more likely to suffer heart attacks, strokes, and other serious cardiovascular events within the first 30 days of treatment initiation.

Conducted by scientists in Taiwan, the study compared the rate of hospitalization for heart problems against the duration since initiation of long-acting inhaler therapy. To do so, the study authors analyzed the medical records of more than 280,000 COPD patients who had been prescribed a long-acting inhaler – either LABAs or long-acting antimuscarinic antagonists (LAMAs) – between 2007 and 2011. The subjects were followed for an average of 2 years.

Patients who used either type of long-acting inhaler were 50% more likely to experience cardiovascular problems like a heart attack or stroke within the first 30 days of initiating treatment. However, the risk did decline over time.

“Based on our findings, we suggest that the use of inhaled long-acting bronchodilators in COPD need to be carefully assessed, and a thorough cardiovascular physical examination, especially heart rate measurement and electrocardiograms, need to be performed when prescribing LABAs and LAMAs to patients,” the study authors wrote.

COPD patients who begin new treatment with a long-acting inhaler should seek medical attention for symptoms that might indicate a heart problem, such as chest pains or a suddenly rapid heart beat.

Filing a Symbicort Lawsuit Can Help

Pharmaceutical companies have a duty to warn patients of the risks and side effects associated with their medications.

Filing a Symbicort lawsuit could help those who may have been injured by this drug, and their surviving family members, obtain compensation for the physical, financial, and emotional damages associated with their injury, including:

  • Medical bills
  • Lost wages
  • Emotional distress
  • Disability
  • Loss of consortium
  • Wrongful death
  • More

To discuss filing a claim with an experienced Symbicort attorney, please fill out our online form or contact our office directly by calling (888) 994-5118.

  1. FDA (2017) “Highlights of Prescribing Information”
  2. JAMA Internal Medicine (January 2, 2018) “Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study”
  3. Reuters (January 2018) “Starting New COPD Inhaler Tied to Heart Attack Risk”
Last Modified: January 11, 2018

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content